Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study

Arne G. C. Bleijenberg, Joep E. G. IJspeert, Yasmijn J. van Herwaarden, Sabela Carballal, Maria Pellise, Gerhard Jung, Tanya M. Bisseling, Iris D. Nagetaal, Monique E. van Leerdam, Niels van Lelyveld, Xavier Bessa, Francisco Rodriguez-Moranta, Barbara Bastiaansen, Willemijn de Klaver, Liseth Rivero, Manon C. W. Spaander, Jan Jacob Koornstra, Luis Bujanda, Francesc Balaguer, Evelien Dekker*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    13 Citations (Scopus)
    45 Downloads (Pure)

    Abstract

    Background and aims Serrated polyposis syndrome (SPS) is associated with an increased risk of colorectal cancer (CRC). International guidelines recommend surveillance intervals of 1-2 years. However, yearly surveillance likely leads to overtreatment for many. We prospectively assessed a surveillance protocol aiming to safely reduce the burden of colonoscopies. Methods Between 2013 and 2018, we enrolled SPS patients from nine Dutch and Spanish hospitals. Patients were surveilled using a protocol appointing either a 1-year or 2-year interval after each surveillance colonoscopy, based on polyp burden. Primary endpoint was the 5-year cumulative incidence of CRC and advanced neoplasia (AN) during surveillance. Results We followed 271 SPS patients for a median of 3.6 years. During surveillance, two patients developed CRC (cumulative 5-year incidence 1.3%[95% CI 0% to 3.2%]). The 5-year AN incidence was 44% (95% CI 37% to 52%), and was lower for patients with SPS type III (26%) than for patients diagnosed with type I (53%) or type I and III (59%, p<0.001). Most patients were recommended a 2-year interval, and those recommended a 2-year interval were not at increased risk of AN: AN incidence after a 2-year recommendation was 15.6% compared with 24.4% after a 1-year recommendation (OR 0.57, p=0.08). Conclusion Risk stratification substantially reduced colonoscopy burden while achieving CRC incidence similar to previous studies. AN incidence is considerable in SPS patients, but extension of surveillance intervals was not associated with increased AN in those identified as low-risk by the protocol. We identified SPS type III patients as low-risk group that might benefit from even less frequent surveillance. Trial registration number The study was registered on http://www.trialregister.nl; trial-ID NTR4609.

    Original languageEnglish
    Pages (from-to)112-121
    Number of pages10
    JournalGut
    Volume69
    Issue number1
    DOIs
    Publication statusPublished - Jan-2020

    Keywords

    • HYPERPLASTIC POLYPOSIS
    • COLORECTAL-CANCER
    • COLONOSCOPY
    • RISK

    Cite this